• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senseonics enters into $50M loan facility

September 11, 2023 By Sean Whooley

Senseonics logoSenseonics (NYSE:SENS) announced today that it entered into a $50 million loan facility with Hercules Capital.

The Germantown, Maryland-based long-term, implantable continuous glucose monitor (CGM) maker drew $25 million upon closing.

Senseonics CFO Rick Sullivan said the facility provides increased financial flexibility for the company. It looks to continue collaborating with Ascensia Diabetes Car to build its Eversense CGM brand and drive global adoption. Recent highlights for the company include the submission of the Eversense CGM system to the FDA for an iCGM designation. Analysts expect this approval to integrate the system with insulin delivery systems to come in 2024.

“This year, we have made significant progress simplifying the company’s capital structure and extending the maturation of our debt to support our growth plans,” Sullivan said in a news release. “The Hercules loan facility strengthens our balance sheet on a non-dilutive basis and is currently expected to provide the capital required to fund our current operating plans to cash flow positivity.”

The loan facility provides for up to $50 million in term loans available in multiple tranches. In addition to the initial $25 million draw, Senseonics may draw an additional tranche of up to $10 million. This may occur for a period of time after achieving revenue milestones.

Senseonics has an additional tranche available for up to $15 million following additional revenue and gross margin milestones. Additionally, the availability of each tranche remains subject to certain conditions. Senseonics is under no obligation to draw funds in the future.

“We are encouraged by the company’s recent progress in expanding their commercial footprint, increasing coverage, and advancing their product pipeline and look forward to their next phase of growth,” said Bryan Jadot, senior managing director and life sciences group head at Hercules.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Implants, Patient Monitoring, Technology Tagged With: Senseonics

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS